Search results for "Psychotic"

showing 10 items of 360 documents

Haloperidol does not antagonize the effects of stress on aggressive behaviour in mice.

1990

The possibility that antipsychotic drugs antagonize the behavioural effects of stress on agonistic behaviour has been explored. Male mice of the OF.1 strain were subjected to the following treatments: 1) Immobilization stress (ten or twenty minutes in duration), 2) haloperidol (three doses) and 3) immobilization stress (ten minutes) plus haloperidol. Individually housed experimental animals confronted standard opponents (anosmic animals) in ten-minute encounters in a neutral cage. Encounters were videotaped and behaviour evaluated, assigning times allocated by subjects to eleven broad behavioural categories. The data show that stress markedly decreases attack behaviour, but haloperidol does…

MaleRestraint Physicalmedicine.medical_specialtyDose-Response Relationship Drugmedicine.medical_treatmentMale miceExperimental and Cognitive PsychologyMice Inbred StrainsDevelopmental psychologyAggressionBehavioral NeuroscienceMiceEndocrinologyInternal medicinemedicineHaloperidolAgonistic behaviourAnimalsHaloperidolRestraint stressAntipsychoticPsychologyArousalAgonistic Behaviormedicine.drugPhysiologybehavior
researchProduct

Psychotic experiences and subjective cognitive complaints among 224 842 people in 48 low- and middle-income countries.

2018

Abstract Aims Cognitive deficits are an important factor in the pathogenesis of psychosis. Subjective cognitive complaints (SCCs) are often considered to be a precursor of objective cognitive deficits, but there are no studies specifically on SCC and psychotic experiences (PE). Thus, we assessed the association between SCC and PE using data from 48 low- and middle-income countries. Methods Community-based cross-sectional data of the World Health Survey were analysed. Two questions on subjective memory and learning complaints in the past 30 days were used to create a SCC scale ranging from 0 to 10 with higher scores representing more severe SCC. The Composite International Diagnostic Intervi…

MaleSYMPTOMSHallucinationsIMPACTAnxietyLogistic regressionGlobal HealthDISEASE0302 clinical medicineCognitionEpidemiologySCHIZOPHRENIAMedicine030212 general & internal medicinelow- and middle-income countriesYoung adultDepression (differential diagnoses)PsychiatryGENERAL-POPULATIONRISKDepressionCognitionIMPAIRMENTDEPRESSIONPREVALENCEPsychiatry and Mental healthAnxietyFemaleepidemiologymedicine.symptomLife Sciences & BiomedicineClinical psychologyMediation (statistics)medicine.medical_specialtyAdolescentlow- and middleincome countrieDelusions03 medical and health sciencesYoung AdultHumanspsychotic experiencesDeveloping CountriesScience & Technologybusiness.industryPublic Health Environmental and Occupational HealthOriginal ArticlesSTRESS SENSITIVITYMental health030227 psychiatryCross-Sectional StudiesPsychotic Disordersbusiness
researchProduct

Hippocampal oscillatory dynamics and sleep atonia are altered in an animal model of fibromyalgia: Implications in the search for biomarkers

2019

The pathogenesis of fibromyalgia is still unknown. Core symptoms include pain, depression, and sleep disturbances with high comorbidity, suggesting alterations in the monoaminergic system as a common origin of this disease. The reserpine-induced myalgia (RIM) model lowers pain thresholds and produces depressive-like symptoms. The present work aims to evaluate temporal dynamics in the oscillatory profiles and motor activity during sleep in this model and to evaluate if the model mimics the sleep disorders that occur in fibromyalgia patients. Hippocampal and electromyogram activity were recorded in chronically implanted rats. Following 3 days of basal recordings, reserpine was administered on…

MaleSleep Wake Disorders0301 basic medicinemyalgiaFibromyalgiaReserpineHippocampusElectromyographyHippocampal formationBiologyHippocampusRats Sprague-Dawley03 medical and health sciences0302 clinical medicineFibromyalgiaMonoaminergicmedicineAnimalsmedicine.diagnostic_testGeneral NeuroscienceChronic painElectroencephalographymedicine.diseaseBrain WavesSleep in non-human animalsRats030104 developmental biologymedicine.symptomSleepNeuroscience030217 neurology & neurosurgeryAntipsychotic AgentsJournal of Comparative Neurology
researchProduct

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: Results from the EU-GEI case-control study

2021

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme. The Brazilian study was funded by grant 2012-0417-0 from the São Paulo Research Foundation. Dr Jongsma is funded by the Economic and Social Research Council (grant ES/S011714/1). Dr Kirkbride is funded by the Wellcome Trust and Royal Society (Grant 101272/Z/13/Z). Dr Jongsma and Professor Jones are funded by the National Institute of Health Research Collaboration of Leadership in Applied Health Research and Care East of England. Professor Rutten is funded…

MaleSocial Determinants of HealthEthnic groupPoison controlIMMIGRANTSOccupational safety and health0302 clinical medicinepsychotic disordersSCHIZOPHRENIADiscriminationOdds RatioApplied PsychologyRISKHYPOTHESISCommunication BarriersLinguistic distanceMiddle AgedDiscrimination; epidemiology; ethnicity; psychotic disorders; social disadvantage3. Good healthSocial researchEuropePsychiatry and Mental healthMIGRANT GROUPSethnicityFemaleepidemiologySTRIATAL DOPAMINE FUNCTIONAdultAdolescentDISORDERSsocial disadvantage1ST EPISODEBlack PeopleLibrary scienceTRANSTORNOS PSICÓTICOSWhite PeopleYoung Adult03 medical and health sciencesFirst episode psychosisPolitical scienceHumansMinority statusINCIDENCE RATESHealth Status DisparitiesOriginal Articlespsychotic disorder030227 psychiatryCase-Control StudiesEthnic and Racial MinoritiesIDENTITYGene-Environment InteractionSocial disadvantage030217 neurology & neurosurgery
researchProduct

Antipsychotic prescription and mortality in hospitalized older persons

2016

Background: Recent scientific reports have shown that older persons treated with antipsychotics for dementia-related behavioural symptoms have increased mortality. However, the impact of these drugs prescribed during hospitalization has rarely been assessed. We aimed to investigate whether antipsychotics are associated with an increased risk of mortality during hospitalization and at 3-month follow-up in elderly inpatients. Methods: We analyzed data gathered during two waves (2010 and 2012) by the REPOSI (Registro Politerapie Società Italiana Medicina Interna). All new prescriptions of antipsychotic drugs during hospitalization, whether maintained or discontinued at discharge, were collect…

MaleSocio-culturaleOlder personAntipsychoticCognitionEconomicaAntipsychotics; Hospitalization; Mortality; Older persons; Gerontology; Geriatrics and Gerontology; Psychiatry and Mental HealthHumansMortalityPsychomotor AgitationAgedantipsychotics hospitalization mortality older personsAged 80 and overMental DisordersPatient DischargeHospitalizationantipsychoticsItalyantipsychotics; hospitalization; mortality; older personsPsychiatry and Mental Healtholder personsDementiaFemaleGeriatrics and GerontologyGerontologyAntipsychotic Agents
researchProduct

The epidemiology of back pain and its relationship with depression, psychosis, anxiety, sleep disturbances, and stress sensitivity: Data from 43 low-…

2016

Background Back pain (BP) is a leading cause of global disability. However, population-based studies investigating its impact on mental health outcomes are lacking, particularly among low- and middle-income countries (LMICs). Thus, the primary aims of this study were to: (1) determine the epidemiology of BP in 43 LMICs; (2) explore the relationship between BP and mental health (depression spectrum, psychosis spectrum, anxiety, sleep disturbances and stress). Methods Data on 190,593 community-dwelling adults aged ≥18 years from the World Health Survey (WHS) 2002–2004 were analyzed. The presence of past-12 month psychotic symptoms and depression was established using questions from the Compos…

MaleStress sensitivitySleep problemsComorbidityAnxietyGlobal Health0302 clinical medicine030212 general & internal medicinepsychosislow- and middle-income countriesDepression (differential diagnoses)Aged 80 and overSleep disordereducation.field_of_studyLow- and middle-income countriesDepressionchronic back painMiddle AgedanxietyBack pain Chronic back pain Mental health Mental illness Depression Psychosis Anxiety Sleep problems Stress sensitivity Low- and middle-income countriesmental illnessAnxiety DisordersPsychiatry and Mental healthMental illnessdepressionAnxietyMental healthFemalemedicine.symptomPsychologymental healthClinical psychologyAnxiety; Back pain; Chronic back pain; Depression; Low- and middle-income countries; Mental health; Mental illness; Psychosis; Sleep problems; Stress sensitivityAdultSleep Wake Disordersmedicine.medical_specialtyAnxiety Back pain Chronic back pain Depression Low- and middle-income countries Mental health Mental illness Psychosis Sleep problems Stress sensitivityAdolescentPopulationChronic back painBF03 medical and health sciencesYoung AdultmedicineHumansPsychiatryeducationDeveloping CountriesAgedsleep problemsDepressive Disorderstress sensitivityBack painOdds ratiomedicine.diseaseMental illnessPsychosisMental healthComorbidityPsychotic DisordersBack Pain030217 neurology & neurosurgeryStress Psychological
researchProduct

Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use

2020

Abstract Psychotic patients with a lifetime history of cannabis use generally show better cognitive functioning than other psychotic patients. Some authors suggest that cannabis-using patients may have been less cognitively impaired and less socially withdrawn in their premorbid life. Using a dataset comprising 948 patients with first-episode psychosis (FEP) and 1313 population controls across 6 countries, we examined the extent to which IQ and both early academic (Academic Factor [AF]) and social adjustment (Social Factor [SF]) are related to the lifetime frequency of cannabis use in both patients and controls. We expected a higher IQ and a better premorbid social adjustment in psychotic p…

MalecognitionIntelligenceComorbiditySUBSTANCE USE DISORDERS0302 clinical medicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.MedicinePREDICTORSRISKeducationeducation.field_of_studybiologyCognitionMiddle AgedPsychosocial FunctioningsociabilityPsychiatry and Mental healthSchizophreniaFemaleMarijuana UseSocial AdjustmentMENTAL-HEALTHAdultmedicine.medical_specialtyPsychosisAdolescentPopulation1ST EPISODEDRUG-USEpreillnessSettore MED/01 - Statistica MedicaYoung Adult03 medical and health sciencesAGESettore M-PSI/08 - Psicologia ClinicaHumansCognitive skilleducationPsychiatrySettore MED/25 - Psichiatriabusiness.industryCase-control studypreillnebiology.organism_classificationmedicine.diseaseEDUCAÇÃO030227 psychiatryschizophreniaPsychotic DisordersCase-Control StudiesONSETCannabisNEUROCOGNITIONbusinessmarijuanaNeurocognitive030217 neurology & neurosurgeryRegular ArticlesSchizophrenia Bulletin
researchProduct

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for mul…

2016

Abstract Background Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports. We aimed to systematically review the efficacy and safety of AceI and memantine across multiple outcome dimensions in BD. Methods Systematic PubMed and SCOPUS search until 04/17/2015 without language restrictions. Included were randomized controlled trials (RCTs), open label studies and case series of AceI or memantine in BD patients reporting quantitative data on depression, mania, psychotic symptoms, global functioning, or cognitive performance. We summarized results using a best-…

Malelaw.inventionpsychosis.0302 clinical medicinePiperidinesRandomized controlled triallawDonepezilDonepezilRandomized Controlled Trials as Topicbipolar disorderClinical Trials as TopicEvidence-Based MedicineDepressionMemantineMiddle AgedManiaPsychiatry and Mental healthClinical PsychologyTreatment Outcomeacetylcholinesterase inhibitorsdepressionIndansFemalemedicine.symptomPsychologyManiamedicine.drugAdultmedicine.medical_specialtyBipolar disorderPlaceboBipolar disorder Acetylcholinesterase inhibitors Memantine Depression Mania Psychosis03 medical and health sciencesmaniaMemantineInternal medicinemedicineGalantamineHumansBipolar disorderAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis.PsychiatryDepressive DisorderGalantaminePsychosismedicine.disease030227 psychiatryAcetylcholinesterase inhibitorsMoodPsychotic DisordersAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis; Psychiatry and Mental Health; Clinical PsychologyCase-Control StudiesmemantineCholinesterase InhibitorsExcitatory Amino Acid Antagonists030217 neurology & neurosurgeryJournal of Affective Disorders
researchProduct

Cannabis use in male and female first episode of non-affective psychosis patients: long-term clinical, neuropsychological and functional differences

2017

BACKGROUND: Numerous studies show the existence of a high prevalence of cannabis use among patients with psychosis. However, the differences between men and women who debut with a first episode of psychosis (FEP) regarding cannabis use have not been largely explored. The aim of this study was to identify the specific sex factors and differences in clinical evolution associated with cannabis use. METHOD: Sociodemographic characteristics at baseline were considered in our sample of FEP patients to find differences depending on sex and the use of cannabis. Clinical, functional and neurocognitive variables at baseline, 1-year, and 3-years follow-up were also explored. RESULTS: A total of 549 pa…

Malelcsh:MedicineSocial Sciences[ SCCO.PSYC ] Cognitive science/PsychologyNeuropsychological TestsDrug UsersCognitionLearning and Memory0302 clinical medicineMedicine and Health SciencesPsychologyYoung adultlcsh:ScienceFirst episodeMultidisciplinarybiologyNeuropsychologyCognitionAddicts3. Good healthBehavioral PharmacologySchizophrenia[ SCCO.NEUR ] Cognitive science/Neuroscience[SCCO.PSYC]Cognitive science/Psychology[SCCO.PSYC] Cognitive science/PsychologyFemaleResearch ArticleAdultPsychosismedicine.medical_specialtyCognitive NeurosciencePsicosiAddictionMarijuana SmokingYoung Adult03 medical and health sciencesMemoryRecreational Drug UseCànnabisMental Health and PsychiatrymedicineHumansFactors sexuals en les malaltiesWorking MemoryPsychiatryCannabisPharmacologybusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/Neurosciencelcsh:RCognitive PsychologyBiology and Life SciencesPsychosesmedicine.diseasebiology.organism_classification030227 psychiatryPsychotic DisordersSchizophreniaCognitive ScienceSex factors in diseaselcsh:QCannabisbusinessNeurocognitive030217 neurology & neurosurgeryNeuroscience
researchProduct

Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice

2008

Efflux transporters, like P-glycoprotein (P-gp), may limit the access of drugs to the brain via the blood-brain barrier. The antipsychotic drug risperidone and its active metabolite 9-hydroxyrisperidone (paliperidone) are substrates of P-gp. Motor behavior of P-gp deficient mice (mdr1a/1b (-/-, -/-)) and wild type animals on a rotarod after acute doses of risperidone or haloperidol, a nonsubstrate of P-gp, were analysed aiming to show that P-gp substrate properties of an antipsychotic drug have functional consequences. Behavioral tests revealed dose-dependent effects of 0.3-3 mg/kg risperidone in wild type animals 0.5-12 h after i.p. injection of the drug. In knockout mice the 0.3 mg/kg dos…

Malemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BTime Factorsmedicine.drug_classAtypical antipsychoticMotor ActivityPharmacologyMiceBehavioral NeurosciencePharmacokineticsInternal medicinePaliperidone PalmitatemedicineHaloperidolAnimalsPaliperidoneATP Binding Cassette Transporter Subfamily B Member 1Chromatography High Pressure LiquidMice KnockoutPaliperidone PalmitateRisperidoneBehavior AnimalDose-Response Relationship DrugChemistryDopamine antagonistBrainIsoxazolesRisperidonePyrimidinesEndocrinologyPsychotropic drugArea Under CurveHaloperidolATP-Binding Cassette TransportersAntipsychotic Agentsmedicine.drugBehavioural Brain Research
researchProduct